Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 11:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 124 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Invasive Fungal Infection Clear all
Completed Phase 2 Interventional Results available

An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With Candidemia

NCT03604705
View directory record Official record
Conditions
Candidemia
Interventions
APX001
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
9
States / cities
Birmingham, Alabama • Davis, California • Sacramento, California + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Jul 22, 2026, 11:09 PM EDT
Completed No phase listed Observational

COVID-19 Associated Pulmonary Aspergillosis (CAPA) and Other Invasive Fungal Infections (IFI)

NCT04818853
View directory record Official record
Conditions
Covid19, Aspergillosis, Fungal Infection
Interventions
Observation to monitor patients for these infections
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Jul 22, 2026, 11:09 PM EDT
Completed No phase listed Observational

Serial Therapeutic and Antifungal Monitoring Protocol

NCT02163889
View directory record Official record
Conditions
Candidemia
Interventions
Not listed
Lead sponsor
T2 Biosystems
Industry
Eligibility
18 Years to 95 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
3
States / cities
Birmingham, Alabama • Pittsburgh, Pennsylvania • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 19, 2018 · Synced Jul 22, 2026, 11:09 PM EDT
Completed Phase 3 Interventional Results available

Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis

NCT03667690
View directory record Official record
Conditions
Candidemia, Mycoses, Fungal Infection, Invasive Candidiases
Interventions
Rezafungin for Injection, Caspofungin, Fluconazole, intravenous placebo, oral placebo
Drug
Lead sponsor
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
19
States / cities
Birmingham, Alabama • Sacramento, California • Atlanta, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2023 · Synced Jul 22, 2026, 11:09 PM EDT
Completed Phase 2 Interventional Results available

CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension

NCT02734862
View directory record Official record
Conditions
Candidemia, Mycoses, Fungal Infection, Fungemia, Invasive Candidiasis
Interventions
CD101, Caspofungin, Fluconazole, intravenous placebo, oral placebo
Drug
Lead sponsor
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
16
States / cities
Birmingham, Alabama • Davis, California • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Jul 22, 2026, 11:09 PM EDT
Completed Phase 3 Interventional Results available

Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant

NCT01503515
View directory record Official record
Conditions
Fungal Infection, Hematopoietic and Lymphoid Cell Neoplasm
Interventions
Caspofungin Acetate, Fluconazole, Laboratory Biomarker Analysis, Voriconazole
Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
3 Months to 20 Years
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
46
States / cities
Phoenix, Arizona • Loma Linda, California • Oakland, California + 38 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Jul 22, 2026, 11:09 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects

NCT00940017
View directory record Official record
Conditions
Aspergillosis, Candidemia
Interventions
anidulafungin and voriconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 8, 2010 · Synced Jul 22, 2026, 11:09 PM EDT
Completed Phase 1 Interventional

Phase I Study of the Safety, Tolerance, and Pharmacokinetics of FK463 in Immunocompromised Children With Fever and Neutropenia

NCT00001790
View directory record Official record
Conditions
Fever, Mycoses, Neutropenia
Interventions
FK463
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 22, 2026, 11:09 PM EDT
Completed Phase 3 Interventional Results available

Anidulafungin Plus Voriconazole Versus Voriconazole For The Treatment Of Invasive Aspergillosis

NCT00531479
View directory record Official record
Conditions
Aspergillosis
Interventions
voriconazole, anidulafungin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
16 Years and older
Enrollment
459 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
26
States / cities
Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2012 · Synced Jul 22, 2026, 11:09 PM EDT
Terminated Phase 4 Interventional Results available

Study to Test the Combination of Voriconazole and Anidulafungin in Patients Who Have, or Are Thought to Have, Invasive Aspergillosis and Who Are Unable to Take a Common Antifungal Therapy (Polyene)

NCT00620074
View directory record Official record
Conditions
Aspergillosis
Interventions
voriconazole, anidulafungin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
Atlanta, Georgia • Detroit, Michigan • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2010 · Synced Jul 22, 2026, 11:09 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Interferon-Gamma 1b in Patients With Candidemia

NCT04979052
View directory record Official record
Conditions
Candidemia
Interventions
Interferon Gamma-1B
Drug
Lead sponsor
Radboud University Medical Center
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Jul 22, 2026, 11:09 PM EDT
Terminated Phase 4 Interventional

Anchoring Sequential Intermittent Long Acting Antimicrobials With Medication for Opioid Use Disorder (MOUD) for Invasive Infections Related to Opioid Use

NCT05521880
View directory record Official record
Conditions
Substance Use Disorders, Infection, Soft Tissue, Bacteremia, Osteomyelitis Acute, Septic Arthritis
Interventions
Oritavancin
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 88 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Jul 22, 2026, 11:09 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and Adults

NCT04886154
View directory record Official record
Conditions
Infections, Meningococcal
Interventions
MenABCWY-2Gen low dose vaccine, MenABCWY-2Gen high dose vaccine, Placebo, MenB vaccine, MenACWY vaccine
Combination Product · Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
10 Years to 50 Years
Enrollment
1,440 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
12
States / cities
Colorado Springs, Colorado • Longmont, Colorado • Doral, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated May 30, 2025 · Synced Jul 22, 2026, 11:09 PM EDT
Completed Phase 2 Interventional Results available

Study Of The Pharmacokinetics And Safety Of Voriconazole In Children 2 To 11 Years Old Who Are At High Risk For Systemic Fungal Infection

NCT00739934
View directory record Official record
Conditions
Candidiasis, Candidemia
Interventions
voriconazole (Vfend)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
2 Years to 11 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
14
States / cities
Tucson, Arizona • Orange, California • Jacksonville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2011 · Synced Jul 22, 2026, 11:09 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Non-Invasive Sexually Transmitted Disease Testing in Women Seeking Emergency Contraception or Urine Pregnancy Testing

NCT00978848
View directory record Official record
Conditions
Trichomonas Vaginitis, Chlamydia Trachomatis, Neisseria Gonorrhoeae Infection
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
15 Years and older · Female only
Enrollment
305 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 17, 2016 · Synced Jul 22, 2026, 11:09 PM EDT
Completed No phase listed Observational

Evaluation of NGS for Detection and Follow-up of Fungal Pathogens in Immunocompromised Pediatric Patients

NCT03262584
View directory record Official record
Conditions
Invasive Fungal Disease, Fever and Neutropenia, Invasive Fungal Infections, Immunocompromised
Interventions
Not listed
Lead sponsor
Karius, Inc.
Industry
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 16, 2019 · Synced Jul 22, 2026, 11:09 PM EDT
Completed Phase 4 Interventional Results available

Study Will Evaluate The Safety And Efficacy Of Anidulafungin In Patients With Candidemia Or Invasive Candidiasis

NCT00496197
View directory record Official record
Conditions
Candidiasis
Interventions
Eraxis (anidulafungin), Diflucan (fluconazole), Vfend (voriconazole)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
39
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2011 · Synced Jul 22, 2026, 11:09 PM EDT
Completed No phase listed Observational

Early Molecular Detection for the Improved Diagnosis of Invasive Pulmonary Aspergillosis and Invasive Pulmonary Zygomycosis

NCT00923832
View directory record Official record
Conditions
Immunocompromised Host, Invasive Pulmonary Fungal Infection, Invasive Pulmonary Aspergillosis, Invasive Pulmonary Zygomycosis
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 22, 2026, 11:09 PM EDT
Completed No phase listed Observational

Clinical Performance of the Accelerate ID/AST System for Positive Blood Culture

NCT02719769
View directory record Official record
Conditions
Bacteremia, Fungemia
Interventions
Not listed
Lead sponsor
Accelerate Diagnostics, Inc.
Industry
Eligibility
Not listed
Enrollment
4,009 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
14
States / cities
Gilbert, Arizona • Tucson, Arizona • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2017 · Synced Jul 22, 2026, 11:09 PM EDT
Completed Phase 4 Interventional Results available

Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome

NCT01200355
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Interventions
micafungin, posaconazole
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 6, 2018 · Synced Jul 22, 2026, 11:09 PM EDT
Completed No phase listed Observational

Registry of Patients Treated With Systemic Mold-Active Triazoles

NCT03066011
View directory record Official record
Conditions
Invasive Fungal Infection
Interventions
Isavuconazonium sulfate, Voriconazole, Posaconazole
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
Not listed
Enrollment
2,015 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
56
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2024 · Synced Jul 22, 2026, 11:09 PM EDT
Completed No phase listed Observational

Detecting Infections Rapidly and Easily for Candidemia Trial (DIRECT)

NCT01525095
View directory record Official record
Conditions
Candidemia
Interventions
Not listed
Lead sponsor
T2 Biosystems
Industry
Eligibility
18 Years to 95 Years
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
5
States / cities
Birmingham, Alabama • San Francisco, California • Lexington, Kentucky + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2014 · Synced Jul 22, 2026, 11:09 PM EDT
Withdrawn Phase 2 Interventional

Trial of Combination Antifungal Therapy (Vori+Mica vs. Vori+Placebo) in Invasive Aspergillosis

NCT01207128
View directory record Official record
Conditions
Aspergillosis
Interventions
Voriconazole, micafungin
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Apr 19, 2012 · Synced Jul 22, 2026, 11:09 PM EDT
Completed No phase listed Observational

BIOPIC: Fungal Biomarkers for Diagnosis and Response to Therapy for Pediatric Candidemia

NCT02220790
View directory record Official record
Conditions
Invasive Candidiasis
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
120 Days to 18 Years
Enrollment
515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
19
States / cities
Little Rock, Arkansas • Orange, California • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2022 · Synced Jul 22, 2026, 11:09 PM EDT